1. Leveraging heterogeneity across multiple datasets increases cell-mixture deconvolution accuracy and reduces biological and technical biases. Issue 1 (December 2018) Authors: Vallania, Francesco; Tam, Andrew; Lofgren, Shane; Schaffert, Steven; Azad, Tej; Bongen, Erika; Haynes, Winston; Alsup, Meia; Alonso, Michael; Davis, Mark; Engleman, Edgar; Khatri, Purvesh Journal: Nature communications Issue: Volume 9:Issue 1(2018) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models. (9th November 2020) Authors: LeBlanc, Heidi; Pearson, Cecelia; Kenkel, Justin; Blum, LIsa; Ho, Po; Luo, Angela; Laura, Richard; Zhou, Matthew; Gregorio, Joshua; Luo, Andrew; Ackerman, Shelley; Safina, Brian; Dornan, David; Alonso, Michael; Kowanetz, Marcin Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A640 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models. (9th November 2020) Authors: LeBlanc, Heidi; Pearson, Cecelia; Kenkel, Justin; Blum, LIsa; Ho, Po; Luo, Angela; Laura, Richard; Zhou, Matthew; Gregorio, Joshua; Luo, Andrew; Ackerman, Shelley; Safina, Brian; Dornan, David; Alonso, Michael; Kowanetz, Marcin Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 603 Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration. (9th November 2020) Authors: Ackerman, Shelley; Hartmann, Felix; Pearson, Cecelia; Gonzalez, Joseph; Ho, Po Yi; Kimmey, Samuel; Luo, Andrew; Ackerman, Benjamin; Lee, Arthur; Laura, Richard; Paik, Jason; Henning, Karla; Jackson, David; Chapin, Steven; Devens, Bruce; Dornan, David; Bendall, Sean; Engleman, Edgar; Alonso, Michael Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A360 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Sharma, Manish; Dumbrava, Ecaterina Ileana; Carvajal, Richard; Catenacci, Daniel; Emens, Leisha; Hanna, Glenn; Juric, Dejan; Kang, Yoon-Koo; Lee, Jeeyun; Lee, Keun-Wook; Li, Bob; Moore, Kathleen; Pegram, Mark; Pohlmann, Paula; Rasco, Drew; Spira, Alexander; Tan, Antoinette; Wang, Ding; Ackerman, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Sharma, Manish; Dumbrava, Ecaterina Ileana; Carvajal, Richard; Catenacci, Daniel; Emens, Leisha; Hanna, Glenn; Juric, Dejan; Kang, Yoon-Koo; Lee, Jeeyun; Lee, Keun-Wook; Li, Bob; Moore, Kathleen; Pegram, Mark; Pohlmann, Paula; Rasco, Drew; Spira, Alexander; Tan, Antoinette; Wang, Ding; Ackerman, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A426 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 603 Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration. (9th November 2020) Authors: Ackerman, Shelley; Hartmann, Felix; Pearson, Cecelia; Gonzalez, Joseph; Ho, Po Yi; Kimmey, Samuel; Luo, Andrew; Ackerman, Benjamin; Lee, Arthur; Laura, Richard; Paik, Jason; Henning, Karla; Jackson, David; Chapin, Steven; Devens, Bruce; Dornan, David; Bendall, Sean; Engleman, Edgar; Alonso, Michael Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A638 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗